Castle Biosciences to Acquire Previse (Capsulomics)

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.

Framework Solutions Acquires Govise, Inc.

September 7, 2023

Healthcare Services

Framework Solutions, a Danbury-based provider of clinical-to-commercial life sciences services, has acquired Govise, Inc., a Santa Ana–based specialist in medical review of commercial/promotional and medical materials. The acquisition (terms undisclosed) expands Frameworks' medical review (MLR) capabilities and broadens its service offering to pharmaceutical, biotech and medical device clients; Frameworks is PE-backed by WestView Capital Partners.

Biosynex S.A. Acquires ProciseDx Inc.

June 13, 2023

Medical Devices

French diagnostics company Biosynex S.A. has acquired ProciseDx Inc., a U.S.-based point-of-care in vitro diagnostics company. The acquisition will help Biosynex commercialize ProciseDx's therapeutic drug monitoring (TDM) tests for infliximab and adalimumab in the United States and accelerate point-of-care biologic drug monitoring.

Castle Biosciences Acquires AltheaDx

April 26, 2022

Healthcare Services

Castle Biosciences (Nasdaq: CSTL) completed its acquisition of AltheaDx, a commercial-stage pharmacogenomics (PGx) molecular diagnostics company focused on mental health. Under the definitive agreement, AltheaDx became a wholly owned subsidiary of Castle, and Castle paid $65.0 million at closing plus up to $75.0 million in potential milestone-based consideration tied to performance and expanded Medicare coverage for IDgenetix.

Castle Biosciences Acquires Cernostics

October 19, 2021

Healthcare Services

Castle Biosciences (Nasdaq: CSTL) has completed the acquisition of Cernostics, Inc., a Pittsburgh-based developer of the TissueCypher spatial biology and AI-driven image analysis platform, for approximately $30 million in initial consideration plus up to $50 million in performance-based milestones. The deal brings the TissueCypher Barrett's Esophagus Assay into Castle's portfolio, expanding the company's diagnostics capabilities into the gastrointestinal and oncology markets and adding an estimated ~$1 billion to Castle's U.S. TAM.

PAVmed Acquires CapNostics LLC

October 7, 2021

Healthcare Services

PAVmed Inc. (NASDAQ: PAVM) announced that a wholly owned subsidiary entered into a definitive membership interests purchase agreement to acquire North Carolina-based CapNostics, LLC, which manufactures EsophaCap, an FDA 510(k)-cleared and CE-mark certified esophageal cell collection device. The deal also includes long-term consulting and manufacturing agreements with CapNostics’ owner Martin Von Dyck and its contract manufacturer.